A Phase 3 interventional study of Cagrilintide and Placebo in Obesity and Overweight, sponsored by Novo Nordisk A/S. Active, not recruiting at 40 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-06.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing cagrilintide in Obesity — 9 open to participants now, 15 under way, 9 of them phase 3. cagrilintide · Obesity.
Among the 36 studies testing cagrilintide in Obesity, this one is the 13th largest by planned enrollment, is one of 6 that started in 2025, is one of 15 in phase 3, reaches primary completion later than 3 of the 14 other live ones, and was the 25th registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →9 of the 36 studies testing cagrilintide in Obesity are open now, in 12 countries. Recruiting first, the newest first:
Novo Nordisk A/S · Sites in United States, Greece, Hungary and 3 more countries
Ages 18+
Novo Nordisk A/S · Sites in United States
Ages 18+
Novo Nordisk A/S · Sites in United States, Argentina, Australia and 16 more countries
Ages 18+
Novo Nordisk A/S · Sites in Germany
Ages 18–64
Novo Nordisk A/S · Sites in Germany
Ages 18–64
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, cagrilintide is the treatment under test here. Read study by study →
36 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 6 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 154 across the 36 interventional studies. Of the 20 that completed or were terminated, 1 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 36 have an industry lead sponsor. The 1 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
207 studies in Obesity by Novo Nordisk A/S: 48 open now, 66 under way, 26 of them phase 3. Of 138 finished, 39 (28%) have results posted.
Among the 207 studies in Obesity by Novo Nordisk A/S, this one is the 55th largest by planned enrollment of the 166 interventional ones that give a count, is one of 22 that started in 2025, is one of 62 in phase 3, reaches primary completion later than 17 of the 65 other live ones, and was the 155th registered.
Novo Nordisk A/S’s Obesity studies by the year they started, since 2007.
8 of the studies testing cagrilintide in Obesity that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07011667Phase 3Novo Nordisk A/SA Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term | 2027-03-01 |
| NCT07220642Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide | 2027-05-11 |
| NCT07220759Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide | 2027-05-12 |
| NCT07745504Phase 3Novo Nordisk A/SA Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight | 2027-05-18 |
| NCT07557953Novo Nordisk A/SA Research Study Looking Into How Cagrilintide Influences Food Intake and Appetite in People With Overweight or Obesity | 2027-04-13 |
Add all 8 to your calendar (.ics) → With an account.
Among the 36 studies testing cagrilintide in Obesity, from their registry updates:
Among Novo Nordisk A/S’s 207 in Obesity:
This tab as a report to print or save as PDF → With an account.
This study will look at how much cagrilintide helps people with overweight or obesity lower their body weight. Cagrilintide is a new investigational medicine. Doctors may not yet prescribe cagrilintide. Participants will either get cagrilintide or placebo. Which treatment participants get is decided by chance. Participants are two times more likely to get cagrilintide than placebo. Like all medicines, the study medicine may have side effects. Possible side effects will be followed carefully during the study. For each participant, the study will last for about 1 year and 6 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive cagrilintide subcutaneously once weekly for 64 weeks.
Drug: Cagrilintide
Participants will receive placebo matched to cagrilintide subcutaneously once weekly for 64 weeks.
Drug: Placebo
Cagrilintide will be administered subcutaneously with a pen-injector as an adjunt to lifestyle intervention counselling.
Placebo matched to cagrilintide will be administered subcutaneously with a pen-injector as an adjunt to lifestyle intervention counselling.
Relative change in body weight
Measured as percentage (%).
Time frame: From baseline (week 0) to end of treatment (week 64)
Number of participants with achievement of greater than or equal to (>=) 10 percent (%) body weight reduction (yes/no)
Measured as count of participants.
Time frame: From baseline (week 0) to end of treatment (week 64)
Number of participants with achievement of >= 15 % body weight reduction (yes/no)
Measured as count of participants.
Time frame: From baseline (week 0) to end of treatment (week 64)
Change in waist circumference
Measured as centimeters (cm).
Time frame: From baseline (week 0) to end of treatment (week 64)
Ratio to baseline in triglycerides
Measured as ratio.
Time frame: From baseline (week 0) to end of treatment (week 64)
Ratio to baseline in high sensitivity C-Reactive Protein (hsCRP)
Measured as ratio.
Time frame: From baseline (week 0) to end of treatment (week 64)
Change in Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT) Physical Function score
Measured as score on a scale. IWQOL-Lite-CT measures weight-related physical and psychosocial functioning. The measure consists of 20 items yielding 3 composite scores, and 1 total score. Higher scores indicate better levels of functioning. The physical function score ranges from 0-100.
Time frame: From baseline (week 0) to end of treatment (week 64)
Change in Systolic Blood Pressure (SBP)
Measured as millimeter of mercury (mmHg).
Time frame: From baseline (week 0) to end of treatment (week 64)
Change in body weight
Measured as kilograms (kg).
Time frame: From baseline (week 0) to end of treatment (week 64)
Number of participants with achievement of >= 5 % body weight reduction (yes/no)
Measured as count of participants.
Time frame: From baseline (week 0) to end of treatment (week 64)
Change in SF-36v2® Health Survey Acute (SF-36v2® Acute) physical component summary score
Measured as score on a scale. SF-36v2 Acute measures Health-Related Quality of Life (HRQoL). The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2 Acute scores are norm-based scores, that is. transformed to a scale where the 2009 US general population has a mean of 50 and a standard deviation of 10. Higher scores indicate better functional health and well-being. The physical component summary score ranges from 6.1 to 79.7.
Time frame: From baseline (week 0) to end of treatment (week 64)
Change in SF-36v2® mental component summary score
Measured as score on a scale. SF-36v2 Acute measures Health-Related Quality of Life (HRQoL). The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2 Acute scores are norm-based scores, that is. transformed to a scale where the 2009 US general population has a mean of 50 and a standard deviation of 10. Higher scores indicate better functional health and well-being. The mental component summary score ranges from -3.8 to 78.7.
Time frame: From baseline (week 0) to end of treatment (week 64)
Change in IWQOL-Lite-CT total score
Measured as score on a scale. IWQOL-Lite-CT measures weight-related physical and psychosocial functioning. The measure consists of 20 items yielding 3 composite scores, and 1 total score. Higher scores indicate better levels of functioning. The total score ranges from 0-100.
Time frame: From baseline (week 0) to end of treatment (week 64)
Number of participants with achievement of at least 14.6-point increase in IWQOL-Lite-CT Physical Function score (yes/no)
Measured as count of participants. IWQOL-Lite-CT measures weight related physical and psychosocial functioning. The measure consists of 20 items yielding 3 composite scores, and 1 total score. Higher scores indicate better levels of functioning. The physical function score ranges from 0-100.
Time frame: From baseline (week 0) to end of treatment (week 64)
Change in Diastolic Blood Pressure (DBP)
Measured as mmHg.
Time frame: From baseline (week 0) to end of treatment (week 64)
Ratio to baseline of total cholesterol
Measured as ratio.
Time frame: From baseline (week 0) to end of treatment (week 64)
Ratio to baseline of High-Density Lipoprotein (HDL) cholesterol
Measured as ratio.
Time frame: From baseline (week 0) to end of treatment (week 64)
Ratio to baseline of Low-Density Lipoprotein (LDL) cholesterol
Measured as ratio.
Time frame: From baseline (week 0) to end of treatment (week 64)
Ratio to baseline of Very Low-Density Lipoprotein (VLDL) cholesterol
Measured as ratio.
Time frame: From baseline (week 0) to end of treatment (week 64)
Ratio to baseline of non-HDL cholesterol
Measured as ratio.
Time frame: From baseline (week 0) to end of treatment (week 64)
Ratio to baseline of free fatty acids
Measured as ratio.
Time frame: From baseline (week 0) to end of treatment (week 64)
Change in glycated haemoglobin (HbA1c) percentage-points (%-points)
Measured as %-points.
Time frame: From baseline (week 0) to end of treatment (week 64)
Change in HbA1c millimoles per mole (mmol/mol)
Measured as mmol/mol.
Time frame: From baseline (week 0) to end of treatment (week 64)
Change in Fasting Plasma Glucose (FPG) millimoles per litre (mmol/L)
Measured as mmol/L.
Time frame: From baseline (week 0) to end of treatment (week 64)
Change in FPG milligrams per deciliter (mg/dL)
Measured as mg/dL.
Time frame: From baseline (week 0) to end of treatment (week 64)
Ratio to baseline in fasting serum insulin
Measured as ratio.
Time frame: From baseline (week 0) to end of treatment (week 64)
Number of treatment emergent adverse events (TEAEs)
Measured as count of events.
Time frame: From baseline (week 0) to end of study (week 71)
Number of treatment emergent serious adverse events (TESAEs)
Measured as count of events.
Time frame: From baseline (week 0) to end of study (week 71)
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Data sharing details ↗ · novonordisk-trials.com
No publications or documents are linked to this record.
Started Nov 2025 (actual). Primary completion is estimated for May 2027, 18 months after the start.
Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's planned 18 months is below that.
Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cagrilintide